Herein, we will address several key questions: (1) the role of CYLD in regulating DDP resistance in ovarian cancer; (2) the downstream effector(s) of CYLD that mediate DDP resistance in ovarian cancer; (3) the signal pathways that may be associated with CYLD expression and cancer progression; (4) the upstream regulator of CYLD, and (5) whether there are new small molecular inhibitors or drugs that can be used to reverse DDP resistance in CYLD knockdown cells. Here, CYLD is linked to ovarian carcinoma.